galantamine
FDA Approved
Description
Galantamine is a reversible, competitive acetylcholinesterase inhibitor that also allosterically modulates nicotinic receptors. While primarily used for Alzheimer's disease, it has been investigated for cognitive and neurological symptoms in various rare genetic conditions. It is available in oral formulations including tablets and extended-release capsules.
Indications & Therapeutic Use
Alzheimer's disease, cognitive impairment
Global Availability (5 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
galantamine
| Generic Name | galantamine |
| Brands | 1 brand available |
| Active Ingredient | galantamine hydrobromide |
| Drug Class | Alzheimer's disease |
| Manufacturer | Janssen Pharmaceuticals |
| Dosage Forms | Oral tablet 4mg, 8mg, 12mg; Extended-release capsule 8mg, 16mg, 24mg |
| Medical Code | N06DA04 |
| Orphan Status | No |
| Cold Chain | Not Required |
| Lead Time | 7 days |
| Reg. Status | FDA Approved |
| Countries | 5 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations6 Validated Nodes